Among these patients, 117 were diagnosed as LGGs (62 diffuse astrocytomas, IDH-mutant, 22 diffuse astrocytomas, IDH-wildtype; 7 diffuse astrocytomas, NOS; 12 oligodendrogliomas, IDH-mutant and 1p19q-codeleted; 14 oligodendrogliomas, NOS), 36 as anaplastic gliomas (AG, WHO Grade III; 13 anaplastic astrocytomas, IDH-mutant; 14 anaplastic astrocytomas, IDH-wildtype; 3 anaplastic oligodendrogliomas, IDH-mutant and 1p19q-codeleted; 5 anaplastic oligodendrogliomas, NOS; 1 anaplastic oligoastrocytoma, NOS), 108 as GBMs (12 GBMs, IDH-mutant; 81 GBMs, IDH-wildtype; 15 GBMs, NOS). This evidence concerns the gene IDH1 and grade III glioma.